A federal final rule effective April 28, 2026 moved FDA-approved marijuana products and marijuana subject to qualifying state medical marijuana licenses into Schedule III. Its scope matters: the rule says other marijuana remains in Schedule I. It also sets federal registration and permit requirements. A state's medical license is not a blanket exemption from every federal obligation, and an adult-use sale is not automatically covered by this medical rule. [1]
DEA separately maintains the proceeding on the broader proposal to transfer marijuana to Schedule III. Its October 22, 2026 order admitted a Government Accountability Office report, declined to reopen testimony, and set November 5 as the reply-brief deadline. That procedural order is not a final decision to reschedule all marijuana. The agency materials reviewed for this article do not establish nationwide adult-use legalization. [2][3]
Our position.
Congress should address criminal penalties, record relief, and market access beyond medical rescheduling. Advocacy should state which products changed category, which activities meet federal requirements, and which people still face penalties.
Questions and next steps.
Will your members of Congress support legislation that addresses federal penalties and record relief beyond medical rescheduling?
Find your lawmakersThis is a dated policy explainer for public discussion. Laws, court orders and implementation dates can change. Check the official sources before relying on a legal detail. How we report and classify policy.